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HISTORICAL PERSPECTIVES
Research into the subject of total artiﬁcial heart (TAH) began in
the USA in 1963 under the impetus of the American Congress;
however, it soon hit the snags of haemocompatibility, autoadjust-
ment of operation to the patient’s physiological needs, miniatur-
ization, portable energy and reliability in the long run.
Michael DeBakey was the ﬁrst to use an external heart pump
successfully in a patient as a left ventricular bypass pump in 1966.
The ﬁrst TAH, called Liotta-Heart, was implanted by Denton Cooley
in 1969 in Houston, TX, USA. The 47-year old male recipient was
bridged for 65 h until heart transplantation was possible. This ﬁrst
TAH was developed by the Argentinian surgeon Domingo Liotta
who was hired at Baylor College of Medicine in Houston, Texas as
Director of the Artiﬁcial Heart Program by Michael DeBakey in
1961 and returned to his homeland later. Finally it remained
unclear how many Liotta-TAHs were implanted.
The next TAH, called Jarvik-7, was implanted in 1982 to a
retired dentist. The patient survived 112 days. The Jarvik-7 heart
led to a remarkable reaction in the media. Meanwhile the original
Jarvik-7 heart was further developed, named CardioWest and
ﬁnally placed on the market under the name Syncardia TAH. The
Syncardia TAH has two pneumatically driven ventricles, separated
from each other and with two mechanical valves each. It was ori-
ginally implanted mainly in Europe (France and then Germany). In
2004, the device was approved by the FDA as a bridge to trans-
plant, allowing several US centres to implant the device. Owing to
the introduction of portable drivers in 2010, patients could now
be discharged home and the utilization of the Syncardia TAH
increased. Over 30 years, more than 1300 were implanted. The
company received a humanitarian device exemption to test its
TAH for destination therapy in 2012, but has not yet begun clinical
trials for this indication. The patient who lived the longest time on
the Syncardia TAH was successfully bridged to heart transplant-
ation after 4 years of support. The Syncardia TAH has ventricles of
70 ml, which does not ﬁt in smaller women and adolescent
patients. Meanwhile, Syncardia started to develop a smaller
version with 50 ml ventricles.
The AbioCor® TAH was developed by the company AbioMed. It
was the world’s ﬁrst fully implantable and completely self-contained
artiﬁcial heart. The internal battery is charged by a transcutaneous
energy transfer (TET) system. A 71-year old man survived for 17
months with the AbioCor TAH. A feasibility study in fourteen
patients and the end-point of 60-day survival led to an initial rejec-
tion by the FDA circulatory system devices advisory panel. In 2006,
the FDA approved the AbioCor TAH as a humanitarian use device
because of its limited market for patients ineligible for transplant-
ation. The device has since been implanted according to our
knowledge in one case (2009).
THE CARMAT TAH
Development of the CARMAT TAH began in 1993 in Paris by a
medical team led by Alain Carpentier in collaboration with an en-
gineering team from Matra Defense, a subsidiary of Airbus Group
(then EADS). In 2008, a company (CARMAT SAS) was founded to
accelerate development and manufacturing of the prosthesis, with
funding from venture capital, the French Innovation Agency and
from an Initial Public Offering in 2010 (CARMAT SA).
The CARMAT TAH contains two chambers, each of which are
separated by a membrane into a blood compartment and a ﬂuid
compartment (www.carmatsa.com). This viscous ﬂuid, put in
motion by two electro-hydraulic pumps, actuates the mem-
branes, producing pulsatile ﬂow. Pressure sensors and electronics
that drive the system and adapt to the patient’s needs are embed-
ded in the prosthesis. Biological valves are placed at the inlets
and outlets of the ventricles. The TAH is connected to the atria
with bioprosthetic suture ﬂanges; Dacron outlet conduits are
sutured onto the aorta and pulmonary artery. The device is par-
tially covered by a ﬂexible compliance bag that contains the actu-
ating ﬂuid (Fig. 1). A percutaneous driveline provides power to
the TAH and retrieves information on device performance. In the
current conﬁguration, the driveline is connected to a hospital
console.
What distinguishes the CARMAT TAH from the
existing artiﬁcial hearts and what are the
challenges?
The blood-contacting surface of the membrane is bioprosthetic
material—processed bovine pericardial tissue—similar to the bio-
logical valves developed by Carpentier in the early 1980s [1, 2].
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The intended beneﬁt of these bioprosthetic materials is improved
haemocompatibility, potentially reducing the risk of bleeding/
thrombosis and the need for prolonged anticoagulation [3]. The
challenge is the long-term durability of the membranes and valves
in this application.
The internal electro-hydraulic actuation of the membranes
eliminates the need for an external actuator (such as Syncardia’s
pneumatic drivers) and, important from a quality-of-life perspec-
tive, produces no audible noise.
The device uses a control algorithm that responds to changes in
preload and afterload, measured by the pressure sensors in the
ventricles. The resulting blood ﬂow ranges from 2–9 l/min, de-
pending on the patient’s needs. This is also a potential improve-
ment in the quality of life.
The sensors, electronics and microprocessor that regulate the
system are embedded inside the prosthesis. While this might
reduce the risk of user-interface errors, failing components cannot
be replaced without explanting the device.
The prosthesis has been designed to mimic the shape of the
natural heart. With the volume of the ventricles (65 ml each), the
actuating liquid and the embedded components, the displace-
ment volume is at least 750 ml. The company provides a
virtual anatomical ﬁt tool to assist in selecting patients who have
enough space in the thoracic cavity. Retrospective studies of 115
thoracic CT scans from patients with cardiac pathologies demon-
strated a virtual ﬁt in 86% of male patients but only 14% of females
(data presented at the Annual Conference of the French Society of
Cardiovascular and Thoracic Surgery, Lyon, 2011). For a wider use
of this TAH, a miniaturized version would be needed [4].
Based on preclinical veriﬁcation and validation studies, the
French National Agency for Medicines and Health Products Safety
(ANSM) authorized a feasibility study on 4 patients in 2013. The
ﬁrst implantation took place in December 2013, in a 76-year old
man ineligible for heart transplant. The ﬁrst experience in man
with this bioprosthetic TAH will be communicated after comple-
tion of the clinical trial.
Conﬂict of interest: Paul Mohacsi is a member of the scientiﬁc
advisory board of CARMAT SA. He does not receive a salary or
any ﬁnancial support. Pascal Leprince is a member of the adverse
event committee of CARMAT’s feasibility study.
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Figure 1: CARMAT TAH. (A) Compliance bag surrounding the prosthesis; atrial suture ﬂanges and ejection conduits. (B) Partially open view of embedded electronics
and motor-pump units.
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